首页>投融资
智康弘义
A+轮
无锡智康弘义生物科技有限公司旨在成为一家持续具有领先创新能力的新药技术和产品公司,公司以临床价值和迫切需求为导向、聚焦临床的难点和热点领域,在研发方向和产品管线上,优先致力于肿瘤、自身免疫、心肺等疾病领域的新药发现、开发和转化。
基本信息
-
公司全称无锡智康弘义生物科技有限公司
-
类型肿瘤治疗创新药物研发商
-
产业领域药品研发/制造、医药研发/制造、生物药、化学药
-
公司人数15~50人
-
地址无锡市滨湖区马山梅梁路88号315室(经营场所:无锡市建筑西路581号24楼)
-
联系电话
-
邮箱shenglan.zhang@biocitypharma.com
-
成立时间2017-12-27
投融资
-
2024-08-01A+轮数亿人民币药明康德无锡金投滨湖产业集团
-
2024-07-31A+轮数亿人民币滨湖产业集团无锡金投药明生物
-
2023-12-08未透露未透露药明康德深圳君智合科技
-
2021-01-26未透露未透露深圳君智合科技
-
2020-07-30股权融资未透露华泰紫金投资国联投资道兴投资闻天下科技集团
- 加载更多
相关投融资企业
收并购
Advanced Accelerator Applications (AAA), a subsidiary of Novartis AG, founded in 2002 by Italian academics as a spin-off from the European Organization for Nuclear Research (CERN, Switzerland), develops diagnostic and therapeutic products, including PET radiopharmaceuticals. The company focuses on Personalized Medicine, aimed at providing treatments tailored to a patient's profile and disease, using predictive, preventive and personalized procedures. In January 2018, AAA became a subsidiary of Novartis AG.In July 2016, the company opened its first US manufacturing facility in Millburn, NJ. The Millburn plant served as a distribution center for NETSPOT.In April 2014, AAA opened a new office in the US located at Manhattan, NY. At that time, the company planned to set up a new manufacturing facility in the US.In February 2012, AAA planned to build a radiopharmaceutical facility in Murcia, Spain. The facility was expected to be completed within 18 months.By December 201
B轮
Veradermics Inc (美国):Veradermics是一家位于美国的生物技术公司,专注于皮肤健康和美容产品的研发。公司的主要研究领域包括皮肤再生、抗衰老和皮肤修复。Veradermics利用其专有的生物材料和技术平台,开发了一系列高效的皮肤护理产品。公司的产品线包括抗衰老面霜、皮肤修复凝胶和皮肤再生面膜等。
B轮
Qnovia, formerly known as Respira Technologies, is focused on developing inhaled drug delivery platforms to deliver drugs for nicotine replacement therapy and cardiopulmonary diseases.In September 2022, the company changed its name from Respira Technologies to Qnovia.In September 2022, the company raised USD 17M in Series A funding led by Blue Ledge Capital, DG Ventures, Evolution VC Partners, Gaingels, TL Capital, and Vice Ventures,